Developing novel oligonucleotide treatments
What we do Our primary project is a next generation topical treatment of eczema (atopic dermatitis) for mild to moderate symptoms
Non-invasive and easy application
Regenerates tissue of the afflicted area
Saves vital immune defenses
Anna-Lena Spetz Founder, Chief Scientific Officer
There is a large unmet need for effective, non-steroid topical treatments for patients suffering from mild-moderate eczema, especially for children and young adults. TIRmed´s immunoregulatory cream has the potential to fill this gap
Latest News
TIRmed Pharma initiates permeability study with leading CRO
TIRmed Pharma have begun a permeability study on their cream targeting Atopic Dermatitis, TIR-C. The study will showcase its ability to penetrate human skin – thus being a critical validation milestone. Furthermore, the study will provide data that will be used to define the concentration necessary of the active oligonucleotide TIR-01 in TIR-C. Joanneum Research, […]
TIRmed Pharma raises 5.4 MSEK in equity for pre-clinical development
Eczema is a common disease affecting up to 20% of children and approximately 3% of adults, with a drugs market estimated up to 75 BSEK worldwide. The intense itch associated with the condition can lead to sleeping disorders, anxiety and depression. There is no cure as of today. The current treatments can ameliorate the symptoms. […]
New publication
Amelioration of Compound 48/80-Mediated Itch and LL-37-Induced Inflammation by a Single-Stranded Oligonucleotide Authors: Aleksandra Dondalska, Elin Rönnberg, Haisha Ma, Sandra Axberg Pålsson, Elin Magnusdottir, Tianle Gao, Lucille Adam, Ethan A. Lerner , Gunnar Nilsson, Malin Lagerström and Anna-Lena Spetz Front. Immunol., 30 September 2020 https://doi.org/10.3389/fimmu.2020.559589